School of Medicine, Universidad Tcnica Particular de Loja, Ecuador Compartir Palabras Clave: Obesidad, sobrepeso, riesgo, cardiovascular, semaglutida Keywords: Obesity, overweight, risk, cardiovascular, semaglutideng Fecha recepcin: 20-03-2025 Fecha aceptacin: 31-03-2025 Fecha publicacin: 07-04-2025 DOI: 10.65183/revind.e13.07 Resumen La obesidad y el sobrepeso cumplen un papel importante en el desarrollo de enfermedades crnicas no transmisibles, las cuales conllevan mltiples complicaciones
The long-term treatment duration for GLP-1 medications is measured in months to years, making sustainable protocols essential
Blood samples for measuring glucagon in plasma were collected shortly before each PET scan with the glucagon tracer only
Related: Eli Lillys Tirzepatide Shows Promise for Keeping Prediabetic Patients Diabetes-Free Participants in the trial were randomly assigned to receive either Zepbound, Wegovy or a placebo, with results measured by weight loss percentage and improvements in metabolic health markers